Felvizumab [HuRSV19VHFNS/VK, RSHZ19, RSV monoclonal antibody, SB209763] is a humanised monoclonal antibody (IgG1) prepared by the humanization of an F protein-specific murine MAb. In in vitro studies, palivizumab, another humanized Mab specific for the F protein of RSV, was 4 to 5-fold more potent than felvizumab in neutralising RSV (Scott, 1999).
Research Grade Felvizumab
Overview
Catalog No.
VK421046
Host species
Humanized
Species reactivity
HRSV-A
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Purity
>95% purity as determined by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1, kappa
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Target
F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1
Purification
Protein A/G purified from cell culture supernatant.
Endotoxin level
Please contact the lab for this information.
Expression system
Mammalian Cells
Accession
P03420
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternative name
SB209763, HuRSV19VHFNS/VK, RSHZ19monoclonalantibody, SB209763, CAS:167747-20-8
Note
For research use only. Not suitable for clinical or therapeutic use.
Description
Images
SDS-PAGE
SDS-PAGE for Research Grade Felvizumab.